Vectans Pharma Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Vectans Pharma General Information

Description

Provider of pharmaceutical development and commercialization services intended to serve patients and healthcare partners. The company provides pharmaceutical development, drug optimization, technology, and marketing of medicines, thereby aiming to bring treatments to market through all phases from commercialization.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Corporate Office
  • 230 Bureaux de la colline
  • 92213 Saint-Cloud
  • France
+33 01
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Corporate Office
  • 230 Bureaux de la colline
  • 92213 Saint-Cloud
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vectans Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Merger/Acquisition 01-Jul-2025 Completed Generating Revenue
To view Vectans Pharma’s complete valuation and funding history, request access »

Vectans Pharma Patents

Vectans Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4149426-B1 Mucoadhesive tablet for the treatment of oropharyngeal fungal infections Active 12-May-2020
EP-4149426-C0 Mucoadhesive tablet for the treatment of oropharyngeal fungal infections Active 12-May-2020
ES-3036600-T3 Mucoadhesive tablet for the treatment of oropharyngeal fungal infections Active 12-May-2020
FR-3110079-A1 Mucoadhesive tablet for the treatment of oropharyngeal fungal infections Pending 12-May-2020
EP-4149426-A1 Mucoadhesive tablet for treating oropharyngeal fungal infections Active 12-May-2020 A61K9/006
To view Vectans Pharma’s complete patent history, request access »

Vectans Pharma Investments (1)

Vectans Pharma’s most recent deal was a Corporate Asset Purchase with Onxeo (Two Non-Core Products). The deal was made on 31-Jul-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Onxeo (Two Non-Core Products) 31-Jul-2017 Corporate Asset Purchase Buildings and Property
To view Vectans Pharma’s complete investments history, request access »

Vectans Pharma FAQs

  • When was Vectans Pharma founded?

    Vectans Pharma was founded in 2015.

  • Where is Vectans Pharma headquartered?

    Vectans Pharma is headquartered in Saint-Cloud, France.

  • What industry is Vectans Pharma in?

    Vectans Pharma’s primary industry is Drug Delivery.

  • Is Vectans Pharma a private or public company?

    Vectans Pharma is a Private company.

  • What is Vectans Pharma’s current revenue?

    The current revenue for Vectans Pharma is .

  • When was Vectans Pharma acquired?

    Vectans Pharma was acquired on 01-Jul-2025.

  • Who acquired Vectans Pharma?

    Vectans Pharma was acquired by Athena Pharmaceutiques and Substipharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process